In the absence of effective treatments for COVID-19, many countries have approved the therapeutic use of blood plasma from recovering patients because it contains antibodies against the coronavirus. But not every type of antibody can neutralize the virus and render it noninfectious. New research published this week in mSphere, an open-access journal of the American Society for Microbiology, explores variation in virus neutralization capabilities, which can vary widely by type of antibody.